{
    "clinical_study": {
        "@rank": "77433", 
        "brief_summary": {
            "textblock": "To evaluate safety and immunogenicity of 2 different HIV-1 peptide candidate vaccines, the\n      UBI HIV-1 MN PND peptide immunogen and the UBI microparticulate monovalent HIV-1 MN branched\n      peptide when administered sequentially by 2 different routes of immunization, parental\n      priming followed by oral boosting."
        }, 
        "brief_title": "A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "After the prescreening, volunteers will be randomized into Group I or Group II. Each group\n      will contain 16 volunteers. At least 5 volunteers in each group must be women. At month 0\n      all volunteers will receive multivalent HIV-1 peptide immunogen or the placebo. Group I will\n      receive the injection in the deltoid and Group II will receive it in the anterior thigh. At\n      months 1, 2 and 8 all patients will receive microparticulate monovalent HIV-1 peptide or the\n      placebo. Follow up will be conducted."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have or be:\n\n          -  Healthy.\n\n          -  Negative ELISA for HIV.\n\n          -  Negative for Hepatitis B surface antigen.\n\n          -  Normal urine dipstick.\n\n          -  Normal history and physical exam.\n\n          -  Availability for follow-up for planned duration of the study (60 weeks).\n\n        Risk Behavior: Required:\n\n          -  Lower or intermediate risk sexual behavior as defined by AVEG.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with any of the following symptoms or conditions are excluded:\n\n          -  Medical or psychiatric condition or occupational responsibilities which preclude\n             subject compliance with the protocol.\n\n          -  Active syphilis. NOTE: If the serology is documented to be a false positive or due to\n             a remote (> 6 months) treated infection, the volunteer is eligible.\n\n          -  Active tuberculosis. NOTE: Volunteers with a positive PPD and a normal chest X-ray\n             showing no evidence of TB and not requiring INH therapy are eligible.\n\n        Patients with any of the following prior conditions are excluded:\n\n          -  History of immunodeficiency, chronic illness, malignancy or autoimmune disease.\n\n          -  History of anaphylaxis or other serious adverse reactions to vaccines.\n\n          -  History of inflammatory gastrointestinal disease, celiac disease or intestinal\n             malignancy.\n\n          -  History of acute gastroenteritis within the past month or gastrointestinal surgery\n             within the past 12 months.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  History of use of immunosuppressive medication.\n\n          -  Live attenuated vaccines within 60 days of study. NOTE: Medically indicated subunit\n             or killed vaccines (e.g., influenza, pneumococcal) are not exclusionary but should be\n             given at least 2 weeks away from HIV immunizations.\n\n          -  Use of experimental agents within 30 days prior to study.\n\n          -  Receipt of blood products or immunoglobulin in the past 6 months.\n\n          -  Prior receipt of HIV vaccines or a placebo recipient in an HIV vaccine trial.\n\n        Risk Behavior:\n\n        Excluded:\n\n          -  Subjects with identifiable higher risk behavior for HIV infection as determined by\n             screening questionnaire designed to identify risk factors for HIV infection.\n\n          -  History of injection drug use within the last 12 months to enrollment.\n\n          -  Higher risk sexual behavior as defined by AVEG."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "36", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000846", 
            "org_study_id": "AVEG 023"
        }, 
        "intervention": [
            {
                "intervention_name": "HIV-1 Peptide Vaccine, Microparticulate Monovalent", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "HIV-1 Peptide Immunogen, Multivalent", 
                "intervention_type": "Biological"
            }
        ], 
        "keyword": [
            "Vaccines, Synthetic", 
            "HIV-1", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "HIV Preventive Vaccine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Univ of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ of Rochester Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98144"
                    }, 
                    "name": "Univ of Washington / Pacific Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.", 
        "overall_official": {
            "last_name": "Mulligan M", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000846"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2002"
    }, 
    "geocoordinates": {
        "Univ of Alabama at Birmingham": "33.521 -86.802", 
        "Univ of Rochester Med Ctr": "43.161 -77.611", 
        "Univ of Washington / Pacific Med Ctr": "47.606 -122.332"
    }
}